Mylan 60 Million Securities Settlement Over Alleged False FDA Compliance Statements

Mylan N.V. agreed to a $60 million settlement to resolve a securities class action alleging that the company and certain former executives made false or misleading statements about FDA inspections and regulatory compliance at some of its facilities, which investors say artificially inflated Mylan’s stock price between Feb. 16, 2016 and May 7, 2019. The settling defendants denied wrongdoing but chose to settle to avoid the expense and uncertainty of continued litigation. Eligible class members are purchasers of Mylan common stock during the class period; the fund will cover claims after deductions (attorneys’ fees up to $15 million and expenses up to $500,000), with an estimated average recovery of roughly $0.11 per damaged share before those deductions. Important procedural dates include an opt-out deadline of May 15, 2026, a fairness hearing on June 15, 2026, and a claims deadline of July 10, 2026. This case matters because securities suits like these hinge on investor reliance and materiality: plaintiffs say corrective disclosures about regulatory problems caused stock losses, invoking federal securities laws (e.g., Rule 10b‑5) that require truthful public statements. In heavily regulated industries such as pharmaceuticals, FDA inspections, warning letters, import bans and related compliance problems can quickly alter a company’s valuation, so investor litigation is a common follow-up to adverse regulatory news. Similar pharma-related securities cases frequently end in settlements without admission of liability, reinforcing the importance for companies to maintain robust compliance programs and accurate, timely disclosures; the settlement’s pro rata allocation and recognized-loss formulas demonstrate the standard mechanics courts use to translate alleged inflation into claimant payouts.